EVE Health Group (ASX:EVE) Under Pressure as Shares Touch a 52-Week Low

Sonal Goyal

26 October 2026 09:46 PM AEDT

EVE Health Group (ASX:EVE) Under Pressure as Shares Touch a 52-Week Low

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

EVE Health Group (ASX:EVE) traded at $0.011, down 26.67%, after touching a 52-week low during the 26 October 2026 session.
ASX noted a fall from $0.015 on 23 October to a low of $0.009 and a significant Volume increase.
The company said a Shareholder formerly associated with it may be disposing of their holding.

EVE Health Group Limited (ASX:EVE) shares touched a 52-week low during the Trading session on 26 October 2026, trading at $0.011, down 26.67% on the day. EVE is an Australian health company that develops and commercialises wellness and pharmaceutical products through its subsidiaries Meluka Australia and Nextract. On the same date it published its reply to an ASX price and volume query.

Reply to the ASX Price and Volume Query

The reply, dated 26 October 2026, reproduces the ASX letter, which referred to a fall in EVE's securities from $0.015 on 23 October 2026 to a low of $0.009 at the time of writing, along with a significant increase in volume from 23 to 26 October. ASX asked whether the company held any unannounced information that could explain the trading.

EVE answered no to that question. On the request for other explanations, it said it understands that a shareholder formerly associated with the company may be disposing of their shareholding, and that this selling may have contributed significantly to the recent trading. The company said it is not aware of any other explanation, confirmed compliance with the Listing Rules including Listing Rule 3.1, and stated that its answers were authorised under its continuous disclosure policy.

ASX price and volume queries are issued under Listing Rule 18.7 and require a response by a stated deadline, which in this case was 2.30pm AWST on 26 October 2026. The letter also reminds companies that, if information required under Listing Rule 3.1 exists and no exception applies, it must be disclosed immediately, which may require a Trading halt request.

FY26 Results Released on 31 August 2026

EVE's Appendix 4E for the year ended 30 June 2026, released on 31 August 2026, reported Revenue from ordinary activities of $1,153,101, a decrease of 33.53% from the prior year. The loss after tax from continuing operations attributable to members was $1,890,753, an increase of 30.13%, and the net loss attributable to members rose 19.67% to the same figure.

Net tangible assets per ordinary security were $0.0031, compared with $0.0023 a year earlier. No dividends were paid, declared or determined during the reporting period, and the company reported no associates, joint ventures or changes in controlled entities. The audited financial statements are contained in the 2026 Annual Report that accompanied the release.

About EVE Health Group

EVE Health Group is described by the company as an Australian-based health Business developing and commercialising evidence-based wellness and pharmaceutical products. Its Subsidiary Meluka Australia and its subsidiary Nextract support consumer and practitioner health products sold across retail, pharmacy and clinical channels. Revenue for FY26 was $1.15 million, which indicates the scale at which the group currently operates.

Net tangible assets per security of $0.0031 is the figure stated in the Appendix 4E, and it can be compared with the traded price of $0.011 on 26 October. The company reported no associates or joint ventures and no changes in controlled entities during the period. Its commentary on the results is contained in the 2026 Annual Report rather than in the one-page Appendix 4E.

Risks

The FY26 figures show lower revenue and a larger loss than the previous year, and the company has not declared dividends. The share price is at fractions of a cent, so small changes in cents translate into large percentage movements. The company has also pointed to selling by a former associated shareholder as a Factor in recent trading, and it has not quantified how much of that holding remains or over what period it may be sold.

Catalysts on Investors' Radar

Items that may follow include any further correspondence from ASX about trading in the stock, notices about changes in substantial holdings if the disposal by the former associated shareholder reaches disclosure thresholds, and the company's next periodic reports. EVE has not announced new product launches or financing arrangements.

Final Perspective

EVE touched a 52-week low on a day of elevated volume and responded to ASX by pointing to possible selling by a former associated shareholder while stating it holds no undisclosed information. The most recent results show lower revenue and a larger loss for FY26.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.